ENTRY       D12592                      Drug
NAME        Omidubicel (USAN);
            Omidubicel-onlv;
            Omisirge (TN)
PRODUCT     OMISIRGE (Gamida Cell)
REMARK      Product: D12592<US>
EFFICACY    Antineoplastic
  TYPE      Cellular therapy product
COMMENT     Indicated for hematologic malignancies who are planned for umbilical cord blood transplantation following myeloablative conditioning to reduce the time to neutrophil recovery and the incidence of infection.
TARGET      CD34 [HSA:947] [KO:K06474]
  PATHWAY   hsa04514(947)  Cell adhesion molecules
            hsa04640(947)  Hematopoietic cell lineage
BRITE       Target-based classification of drugs [BR:br08310]
             Cell surface molecules and ligands
              Other cell surface molecules
               CD molecules
                CD34
                 D12592  Omidubicel (USAN) &lt;US&gt;
            New drug approvals in the USA [br08319.html]
             Cellular and gene therapy products
              D12592
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D12592
///
